Cyclooxygenases: Mediators of UV-induced skin cancer and potential targets for prevention

Journal of Investigative Dermatology

Volumn 134, Issue 10, 2014, Pages 2497-2502

  Elmets, Craig A ^a,b,c,d   J Ledet, Johnathan ^a,d   Athar, Mohammad ^a,b,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DNA METHYLTRANSFERASE; FIBRONECTIN; INDOMETACIN; MITOGEN ACTIVATED PROTEIN KINASE; NERVE CELL ADHESION MOLECULE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; SUNSCREEN;

APOPTOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER THERAPY; CELL ADHESION; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DNA METHYLATION; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NON MELANOMA SKIN CANCER; NONHUMAN; ONCOGENE C FOS; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN CARCINOGENESIS; ULTRAVIOLET IRRADIATION; ULTRAVIOLET RADIATION; WILD TYPE; ADVERSE EFFECTS; ANIMAL; DISEASE MODEL; DRUG EFFECTS; NEOPLASMS, RADIATION-INDUCED; PATHOPHYSIOLOGY; PHYSIOLOGY; SKIN NEOPLASMS;

ANIMALS; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; HUMANS; MICE; NEOPLASMS, RADIATION-INDUCED; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SKIN NEOPLASMS; SUNSCREENING AGENTS; ULTRAVIOLET RAYS;

EID: 84926099866     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.192     Document Type: Review

References (49)

1. An KP, Athar M, Tang X et al. (2002) Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol 76:73-80
2. Ansari KM, Rundhaug JE, Fischer SM et al. (2008) Multiple signaling pathways are responsible for prostaglandin E2-induced murine keratinocyte proliferation. Mol Cancer Res 6:1003-16
3. Asgari MM, Chren M-M, Warton EM et al. (2010) Association between nonsteroidal anti-inflammatory drug use and cutaneous squamous cell carcinoma. Arch Dermatol 146:388-95
4. Athar M, An KP, Tang X et al. (2004) Photoprotective effects of sulindac against ultraviolet B-induced phototoxicity in the skin of SKH-1 hairless mice. Toxicol Appl Pharmacol 195:370-8
5. Blackler R, Syer S, Bolla M et al. (2012) Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS One 7:e35196
6. Brecher AR (2002) The role of cyclooxygenase-2 in the pathogenesis of skin cancer. J Drugs Dermatol 1:44-7
7. Buckman SY, Gresham A, Hale P et al. (1998) COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 19:723-9
8. Butler GJ, Neale R, Green AC et al. (2005) Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol 53:966-72
9. Chaudhary SC, Singh T, Kapur P et al. (2013) Nitric oxide-releasing sulindac is a novel skin cancer chemopreventive agent for UVB-induced photocarcinogenesis. Toxicol Appl Pharmacol 268:249-55
10. Christenson LJ, Borrowman TA, Vachon CM et al. (2005) Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 294:681-90
11. Chung HT, Burnham DK, Robertson B et al. (1986) Involvement of prostaglandins in the immune alterations caused by the exposure of mice to ultraviolet radiation. J Immunol 137:2478-84
12. Clouser MC, Roe DJ, Foote JA et al. (2009) Effect of non-steroidal antiinflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial. Pharmacoepidemiol Drug Saf 18:276-83
13. Derry S, Loke YK (2000) Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 321:1183-7
14. Elmets CA, Viner JL, Pentland AP et al. (2010) Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 102:1835-44
15. Faurschou A, Wulf HC (2007) The relation between sun protection factor and amount of suncreen applied in vivo. Br J Dermatol 156:716-9
16. Fischer S, Lo H, Gordon G et al. (1999) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 25:231-40
17. Fischer SM, Hawk ET, Lubet RA (2011) Coxibs and other nonsteroidal antiinflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res 4:1728-35
18. Fischer SM, Pavone A, Mikulec C et al. (2007) Cyclooxygenase-2 expression is critical for chronic UV-induced murine skin carcinogenesis. Mol Carcinog 46:363-71
19. Fosbol EL, Gislason GH, Jacobsen S et al. (2009) Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 85:190-7
20. Gibbs NK, Norval M (2013) Photoimmunosuppression: a brief overview. Photodermatol Photoimmunol Photomed 29:57-64
21. Grau MV, Baron JA, Langholz B et al. (2006) Effect of NSAIDs on the recurrence of nonmelanoma skin cancer. Int J Cancer 119: 682-6
22. Green A, Williams G, Neale R et al. (1999) Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamouscell carcinomas of the skin: a randomised controlled trial. Lancet 354:723-9
23. Johannesdottir SA, Chang ET, Mehnert F et al. (2012) Nonsteroidal antiinflammatory drugs and the risk of skin cancer: a population-based casecontrol study. Cancer 118:4768-76
24. Kawamori T, Rao CV, Seibert K et al. (1998) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58:409-12
25. Kerr DJ, Dunn JA, Langman MJ et al. (2007) Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 357:360-9
26. Kripke ML (1974) Antigenicity of murine skin tumors induced by ultraviolet light. J Natl Cancer Inst 53:1333-6
27. Krutmann J, Honigsmann H, Elmets C (eds) (2009) Dermatological Phototherapy and Photodiagnostic Methods. Springer: Berlin
28. Lee JM, Yanagawa J, Peebles KA et al. (2008) Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 66:208-17
29. Meyskens FL Jr, McLaren CE, Pelot D et al. (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 1:32-8
30. Mikulec CD, Rundhaug JE, Simper MS et al. (2013) The chemopreventive efficacies of nonsteroidal anti-inflammatory drugs: the relationship of short-term biomarkers to long-term skin tumor outcome. Cancer Prev Res (Phila) 6:675-85
31. Nunes AP, Lapane KL, Weinstock MA et al. (2011) Association between non-steroidal anti-inflammatory drugs and keratinocyte carcinomas of the skin among participants in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Pharmacoepidemiol Drug Saf 20: 922-9
32. Pentland A, Schoggins J, Scott G et al. (1999) Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 20:1939-44
33. Pentland AP, Scott G, VanBuskirk J et al. (2004) Cyclooxygenase-1 deletion enhances apoptosis but does not protect against ultraviolet light-induced tumors. Cancer Res 64:5587-91
34. Prasad R, Katiyar SK (2013) Prostaglandin E2 promotes UV radiation-induced immune suppression through DNA hypermethylation. Neoplasia 15: 795-804
35. Ray WA, Stein CM, Hall K et al. (2002) Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 359:118-23
36. Rodriguez-Burford C, Tu JH, Mercurio M et al. (2005) Selective cyclooxygenase-2 inhibition produces heterogeneous erythema response to ultraviolet irradiation. J Invest Dermatol 125:1317
37. Rogers HW, Coldiron BM (2013) Analysis of skin cancer treatment and costs in the United States Medicare population, 1996-2008. Dermatol Surg 39:35-42
38. Rogers HW, Weinstock MA, Harris AR et al. (2010) Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 146:283-7
39. Rundhaug JE, Fischer SM (2008) Cyclo-oxygenase-2 plays a critical role in UV-induced skin carcinogenesis. Photochem Photobiol 84: 322-9
40. Rundhaug JE, Mikulec C, Pavone A et al. (2007) A role for cyclooxygenase-2 in ultraviolet light-induced skin carcinogenesis. Mol Carcinog 46:692-8
41. Rundhaug JE, Simper MS, Surh I et al. (2011) The role of the EP receptors for prostaglandin E2 in skin and skin cancer. Cancer Metastasis Rev 30:465-80
42. Schwarz T (2008) 25 years of UV-induced immunosuppression mediated by T cells-from disregarded T suppressor cells to highly respected regulatory T cells. Photochem Photobiol 84:10-8
43. Seukeran D, Newstead C, Cunliffe W (1998) The compliance of renal transplant recipients with advice about sun protection measures. Br J Dermatol 138:301-3
44. Sharma SD, Katiyar SK (2010) Dietary grape seed proanthocyanidins inhibit UVB-induced cyclooxygenase-2 expression and other inflammatory mediators in UVB-exposed skin and skin tumors of SKH-1 hairless mice. Pharm Res 27:1092-102
45. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11-30
46. Solomon SD, McMurray JJV, Pfeffer MA et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071-80
47. Solomon SD, Wittes J, Finn PV et al. (2008) Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117:2104-13
48. Soontrapa K, Honda T, Sakata D et al. (2011) Prostaglandin E2-prostoglandin E receptor subtype 4 (EP4) signaling mediates UV irradiationinduced systemic immunosuppression. Proc Natl Acad Sci USA 108: 6668-73
49. Steele VE, Rao CV, Zhang Y et al. (2009) Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers. Cancer Prev Res 2:951-6